Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5834450 | 0.68 | TRPA1 (0.34) | TRPA1GPR84 | |
| SCHEMBL31287195 | 0.68 | TRPA1 (0.34) | TRPA1GPR84 | |
| SCHEMBL29643017 | 0.64 | GPR84 (0.37) | TRPA1GPR84 | |
| Dibenzo[B,F][1,4]Thiazepine SCHEMBL696578 | 0.63 | TRPA1 (1.00) | TRPA1BACE1GPR84DRD2 | |
| SCHEMBL882180 | 0.62 | TRPA1 (0.36) | TRPA1BACE1DRD2 | |
| SCHEMBL17103733 | 0.62 | TRPA1 (0.36) | TRPA1BACE1DRD2 | |
| SCHEMBL11818614 | 0.61 | HDAC6 (0.33) | TRPA1BACE1HDAC6DRD2 | |
| SCHEMBL21835118 | 0.61 | TRPA1 (0.35) | TRPA1BACE1DRD2 | |
| SCHEMBL27411802 | 0.61 | CYP11B2 (0.42) | TRPA1GPR84 | |
| SCHEMBL29352703 | 0.60 | TRPA1 (0.45) | TRPA1BACE1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175926-A1 | TARGETED SYNERGISTIC CANCER IMMUNOTHERAPY | BRIGHAM & WOMENS HOSPITAL INC (US) | 2022-06-09 | — | — | US | claimed |
| EP-3946456-A1 | TARGETED SYNERGISTIC CANCER IMMUNOTHERAPY | The Brigham and Women's Hospital, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| WO-2020205729-A1 | TARGETED SYNERGISTIC CANCER IMMUNOTHERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-10-08 | — | — | WO | claimed |
| US-9107948-B2 | Compounds for diagnosing diseases associated with the expression of MUC5AC | GUERBET (FR) | 2015-08-18 | — | — | US | claimed |
| US-9011819-B2 | Optical imaging contrast agents and uses thereof | TARGESON, INC. (US) | 2015-04-21 | — | — | US | claimed |
| US-20120244078-A1 | OPTICAL IMAGING CONTRAST AGENTS AND USES THEREOF | TARGESON, INC. (US) | 2012-09-27 | — | — | US | claimed |
| EP-2480127-A1 | OPTICAL IMAGING CONTRAST AGENTS AND USES THEROF | Targeson, Inc. (US) | 2012-08-01 | — | — | EP | claimed |
| WO-2011038043-A1 | OPTICAL IMAGING CONTRAST AGENTS AND USES THEROF | TARGESON, INC. (US) | 2011-03-31 | — | — | WO | claimed |
| WO-2005058153-A2 | OPTICAL IMAGING CONTRAST AGENTS COMPRISING A TARGETING VECTOR LINKED TO A FLUOROPHORE | AMERSHAM HEALTH AS (NO) | 2005-06-30 | — | — | WO | claimed |
| US-20240139252-A1 | TREATMENT OF VON WILLEBRAND DISEASE | CELLPHIRE, INC. (US) | 2024-05-02 | — | — | US | disclosed |
| US-11965178-B2 | Platelets loaded with anti-cancer agents | CELLPHIRE, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240077837-A1 | SYSTEMS AND METHODS FOR INDICATING THE TIME ELAPSED SINCE THE OCCURRENCE OF A TRIGGERING EVENT | JOHNSON & JOHNSON VISION CARE (US) | 2024-03-07 | — | — | US | disclosed |
| US-11903971-B2 | Treatment of von Willebrand disease | CELLPHIRE, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240042068-A1 | CASPASE-3-TRIGGERED MOLECULAR SELF-ASSEMBLING PET PROBES AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-02-08 | — | — | US | disclosed |
| WO-1998057667-A1 | METHODS OF PHOTOACOUSTIC IMAGING | NYCOMED IMAGING AS (NO) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998052609-A1 | SONODYNAMIC THERAPY USING AN ULTRASOUND SENSITIZER COMPOUND | NYCOMED IMAGING AS (NO) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998048845-A1 | METHOD OF DEMARCATING TISSUE | NYCOMED IMAGING AS (NO) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998047541-A1 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998018496-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-05-07 | — | — | WO | disclosed |
| WO-1998018497-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240042068-A1 | CASPASE-3-TRIGGERED MOLECULAR SELF-ASSEMBLING PET PROBES AND USES THEREOF | CASP3, CASP14, CASP6 | TRPA1 2202/4885BACE1 47/4885GPR84 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.